Piper Sandler raised the firm’s price target on Cigna (CI) to $394 from $392 and keeps an Overweight rating on the shares. The firm notes Cigna reported a pharmacy-led Q3 adjusted EPS beat and reiterated adjusted 2024 guidance. Notwithstanding the asset sale at Cigna Healthcare and VillageMD headwind at Evernorth, CI expects 10.0%-plus consolidated adjusted EPS growth in 2025 vs. long-term target range of 10.0% to 14.0%, Piper adds.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Cigna price target raised to $420 from $405 at Barclays
- Cigna price target lowered to $394 from $398 at Deutsche Bank
- Cigna price target lowered to $391 from $400 at TD Cowen
- Cigna Healthcare, Infirmary Health reach Medicare Advantage agreement
- Cigna Reports Strong Q3 2024 Results with Revenue Surge